Salesforce (CRM) Stock Forecast & Price Target

Q: What analysts cover Salesforce?

Salesforce has been rated by research analysts at Argus , Barclays , BMO Capital Markets , BTIG Research , Canaccord Genuity Group , Cantor Fitzgerald , Citigroup , Citizens Jmp , CLSA , DA Davidson , Deutsche Bank Aktiengesellschaft , Erste Group Bank , Evercore , Guggenheim , HC Wainwright , Jefferies Financial Group , JPMorgan Chase & Co. , KeyCorp , Mizuho , Monness Crespi & Hardt , Morgan Stanley , Needham & Company LLC , Oppenheimer , Phillip Securities , Raymond James Financial , Royal Bank Of Canada , Sanford C. Bernstein , Scotiabank , Stifel Nicolaus , Susquehanna , TD Cowen , The Goldman Sachs Group , Truist Financial , UBS Group , Wedbush , Weiss Ratings , Wells Fargo & Company , and Wolfe Research in the past 90 days.

$250.64 -5.01 (-1.96%)

As of 01:08 PM Eastern

Compare

Salesforce - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 48 Analyst Ratings

Sell
3

Hold
14

Buy
31

Based on 48 Wall Street analysts who have issued ratings for Salesforce in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 48 analysts, 3 have given a sell rating, 14 have given a hold rating, 28 have given a buy rating, and 3 have given a strong buy rating for CRM.

Consensus Price Target

$267.50
6.73% Upside

According to the 48 analysts' twelve-month price targets for Salesforce, the average price target is $267.50. The highest price target for CRM is $400.00, while the lowest price target for CRM is $160.00. The average price target represents a forecasted upside of 6.73% from the current price of $250.64.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for CRM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Salesforce and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CRM Analyst Ratings Over Time

Type	Current Forecast 9/16/25 to 9/16/26	1 Month Ago 8/17/25 to 8/17/26	3 Months Ago 6/18/25 to 6/18/26	1 Year Ago 9/16/24 to 9/16/25
Strong Buy	3 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	28 Buy rating(s)	25 Buy rating(s)	27 Buy rating(s)	26 Buy rating(s)
Hold	14 Hold rating(s)	17 Hold rating(s)	9 Hold rating(s)	10 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$267.50	$249.05	$257.61	$332.58
Forecasted Upside	6.73% Upside	30.26% Upside	69.85% Upside	39.10% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

CRM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Salesforce Stock vs. The Competition

Type	Salesforce	Technology Companies	Broader Market
Consensus Rating Score	2.65	2.23	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	4.61% Upside	437.44% Upside	17.23% Upside
News Sentiment Rating	Positive News See Recent CRM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/16/2026	Mizuho 3 of 5 stars	Gregg Moskowitz 1 of 5 stars	Boost Target	Outperform	$265.00 ➝ $280.00	+11.63%
9/11/2026	Stifel Nicolaus 4 of 5 stars	Parker Lane 1 of 5 stars	Reiterated Rating	Buy	$275.00	+10.52%
9/11/2026	UBS Group 4 of 5 stars	Karl Keirstead 3 of 5 stars	Reiterated Rating	Buy
9/2/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keith Weiss Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$315.00	+22.09%
9/2/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Berg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$400.00	+57.05%
9/2/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allan Verkhovski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$300.00	+16.28%
9/2/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew VanVliet Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$250.00 ➝ $300.00	+16.28%
8/31/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Bonner Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$290.00 ➝ $300.00	+16.91%
8/27/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rishi Jaluria Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$210.00 ➝ $250.00	+2.56%
8/27/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$240.00 ➝ $280.00	+14.87%
A new kind of civil war is coming after election day? (Ad) Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio. Read Whitney Tilson's free analysis on what could happen next.
8/27/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
8/27/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Strong-Buy
8/27/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
8/27/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
8/27/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John DiFucci Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$228.00	+10.67%
8/27/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Schwartz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$250.00 ➝ $275.00	+12.82%
8/27/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Raimo Lenschow Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$236.00 ➝ $276.00	+33.97%
8/27/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brent Thill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$250.00 ➝ $300.00	+45.62%
8/27/2026	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gil Luria Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$175.00 ➝ $200.00	-2.92%
8/27/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mark Moerdler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform
8/27/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
8/27/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tyler Radke Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$204.00 ➝ $233.00	-8.30%
8/27/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mark Murphy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$250.00 ➝ $265.00	+5.25%
8/27/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keith Bachman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$230.00 ➝ $260.00	+6.66%
8/27/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Turrin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$205.00 ➝ $230.00	-4.99%
8/27/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terry Tillman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$280.00 ➝ $300.00	+45.62%
8/27/2026	Monness Crespi & Hardt Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian White Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$222.00 ➝ $266.00	+29.12%
8/25/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Hynes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$225.00	+7.56%
8/25/2026	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Walravens Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Outperform	$315.00	+50.58%
8/12/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Sell (D+) ➝ Hold (C-)
8/5/2026	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
7/20/2026	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bhavtosh Vajpayee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Hold	$165.00	-3.62%
7/8/2026	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jackson Ader Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Sector Weight
7/1/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Ives Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform
7/1/2026	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Neutral
6/29/2026	Phillip Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$253.00 ➝ $166.00	+4.91%
6/18/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Sector Outperform ➝ Sector Perform
6/18/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Negative
6/2/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$295.00 ➝ $280.00	+53.24%
5/29/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$350.00 ➝ $356.00	+86.39%
NNVC on Alert: FDA Validation and Outperform Rating! (Ad) NanoViricides (NYSE: NNVC) just landed FDA Rare Pediatric Disease Designation for NV-387 in Measles, adding to its existing Orphan Drug Designation and opening a path toward a Priority Review Voucher, assets that have recently sold for around 195 million dollars. Noble Capital Markets initiated coverage with an Outperform rating and a 6 dollar price target, citing NNVC's broad-spectrum nanoviricide technology and its potential across Measles, MPox, Smallpox, and Ebola, where a Phase II trial is advancing in the Democratic Republic of Congo. See why analysts are watching NNVC's antiviral pipeline now
5/28/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Billy Fitzsimmons Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
5/28/2026	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$325.00	+82.72%
5/28/2026	Macquarie Infrastructure Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Koenig Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$200.00 ➝ $190.00	+5.84%
5/28/2026	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Craig Ellis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$205.00 ➝ $240.00	+33.36%
5/18/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tal Liani Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy ➝ Underperform	$160.00	-7.93%
3/10/2026	Northland Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nehal Chokshi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Perform	$267.00 ➝ $229.00	+15.24%
12/11/2025	Arete Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
12/4/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rob Oliver Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$325.00 ➝ $315.00	+32.09%
5/30/2025	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brett Huff Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$311.00 ➝ $309.00	+16.88%
5/28/2025	Westpark Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Curtis Shauger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$320.00	+15.55%
2/27/2025	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yun Kim Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$330.00 ➝ $300.00	+0.80%
2/19/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Omar Sheikh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy
10/17/2024	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Aaron Siegel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$343.00	+16.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:08 PM ET.

Should I Buy Salesforce Stock? CRM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 14, 2026. Please send any questions or comments about these Salesforce pros and cons to contact@marketbeat.com.

Salesforce
Bull Case

Here are some ways that investors could benefit from investing in Salesforce, Inc.:

Salesforce, Inc. recently reported a significant earnings beat, delivering $5.90 in earnings per share for the quarter compared to the consensus estimate of $3.27, which demonstrates strong profitability and operational efficiency that can drive shareholder value.
The company is aggressively returning capital to shareholders, having spent a record $27.1 billion on share buybacks in the first quarter alone, which reduces the number of outstanding shares and can increase the earnings per share for remaining investors.
Analyst sentiment remains positive with a consensus rating of Moderate Buy and an average price target of $267.12, suggesting that the current market price of $259.29 still offers potential upside as institutions like Cantor Fitzgerald have recently raised their targets to $300.00.
Salesforce, Inc. is expanding its artificial intelligence capabilities through potential acquisitions, such as the reported interest in Listen Labs for up to $2 billion, which strengthens its agentic AI strategy and positions the company to compete effectively in the evolving enterprise software landscape.
The stock has shown strong recent momentum, trading 4.7% higher to $259.29 on September 14, 2026, and significantly outperforming its 50-day moving average of $200.54, indicating robust investor confidence and upward price trends.

Salesforce
Bear Case

Investors should be bearish about investing in Salesforce, Inc. for these reasons:

There is growing market concern regarding the competitive threat from general AI agents, as evidenced by the stock falling roughly 4% on September 8 when OpenAI launched GPT-6 Astra, which raised fears that specialist software like Salesforce, Inc. could face increased competition from broader AI models.
Some institutional investors are reducing their exposure, with firms like Integrated Wealth Concepts LLC decreasing their holdings by 25.4% and Corient Private Wealth LP cutting their position by 32.1% during the second quarter, suggesting a potential shift in institutional sentiment.
The company carries a debt-to-equity ratio of 1.02, which indicates a moderate level of leverage that could impact financial flexibility, particularly if interest rates remain elevated or if the company faces unexpected operational challenges.
Recent insider activity includes sales by directors, such as Craig Conway selling 4,500 shares at an average price of $260.61 on September 4, which may signal that insiders are taking profits at current valuation levels.
The stock is trading near its 52-week high of $269.11, which may limit short-term upside potential and increase the risk of a pullback if the market sentiment shifts or if the company fails to meet the high expectations set by its recent earnings beats.

CRM Forecast - Frequently Asked Questions

According to the research reports of 48 Wall Street equities research analysts, the average twelve-month stock price forecast for Salesforce is $267.50, with a high forecast of $400.00 and a low forecast of $160.00.

48 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Salesforce in the last year. There are currently 3 sell ratings, 14 hold ratings, 28 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRM shares.

According to analysts, Salesforce's stock has a predicted upside of 6.73% based on their 12-month stock forecasts.

Over the previous 90 days, Salesforce's stock had 9 upgrades and 9 downgrades by analysts.

Salesforce has been rated by research analysts at Argus, Barclays, BMO Capital Markets, BTIG Research, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Citizens Jmp, CLSA, DA Davidson, Deutsche Bank Aktiengesellschaft, Erste Group Bank, Evercore, Guggenheim, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., KeyCorp, Mizuho, Monness Crespi & Hardt, Morgan Stanley, Needham & Company LLC, Oppenheimer, Phillip Securities, Raymond James Financial, Royal Bank Of Canada, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, Susquehanna, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Wedbush, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like Salesforce more than other "technology" companies. The consensus rating for Salesforce is Moderate Buy while the average consensus rating for "technology" companies is Hold. Learn more on how CRM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Salesforce Recommendations

MarketBeat monitors more than a dozen sources for Salesforce analyst ratings, with the most recent rating issued on 9/16/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Salesforce (CRM) Stock Forecast & Price Target